The Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) was funded by the National Institute of Allergy and Infectious Diseases to overcome the major immunological roadblocks in HIV vaccine design and development. More

Press Releases

A T cell and the Human Immunodeficiency Virus

Unique individual demonstrates desired immune response to HIV virus
March 10, 2014
Duke News and Communications

As luck would have it: one of the proteins in milk protects infants against HIV infection
The Economist
October 26, 2013

New artificial protein mimics a part of the HIV outer coat
Duke News and Communications
October 21, 2013

Recent Publications

CD4-mimetic Small Molecules Sensitize Human Immunodeficiency Virus (HIV-1) to Vaccine-elicited Antibodies.
Madani N, Princiotto AM, Schön A, Lalonde J, Feng Y, Freire E, Park J, Courter JR, Jones DM, Robinson J, Liao HX, Moody MA, Permar S, Haynes B, Smith AB 3rd, Wyatt R, Sodroski J. J Virol. 2014 Apr 2. [Epub ahead of print]

IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria
Hwang KK, Trama AM, Kozink DM, Chen X, Wiehe K, Cooper AJ, Xia SM, Wang M, Marshall DJ, Whitesides J, Alam M, Tomaras GD, Allen SL, Rai KR, McKeating J, Catera R, Yan XJ, Chu CC, Kelsoe G, Liao HX, Chiorazzi N, Haynes BF. PLoS One. 2014 Mar 10; 9(3): e90725.

Video Presentations

Broadly neutralizing HIV-1 antibody identified in a lupus patient
March 11, 2014
Dr. Barton Haynes, Duke CHAVI-ID Director, discusses recent findings from a study led by Duke CHAVI-ID investigators in which a broadly neutralizing antibody was identified in a lupus patient who was chronically infected with HIV.